• Explore /
  • Poster
  • / A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus either Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus either Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.

Abstract Poster

Authors

null

Thomas J. Herzog

University of Cincinnati, University of Cincinnati Cancer Institute, Cincinnati, OH

Thomas J. Herzog , Sharad A. Ghamande , Hani Gabra , Deborah Kay Armstrong , Keiichi Fujiwara , Bradley J. Monk , Sandro Pignata , Antonio Gonzalez-Martin , Jalid Sehouli , Charles Schweizer , Susan Weil , Kimberly Hoffman , Luigi Grasso , Robert L. Coleman , Ignace Vergote

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT 022899950

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS5608)

DOI

10.1200/JCO.2016.34.15_suppl.TPS5608

Abstract #

TPS5608

Poster Bd #

425b

Abstract Disclosures

Similar Posters

First Author: Yuanming Shen

First Author: Matthew Raymond Smith

First Author: Dana Shelton Thompson

First Author: Yuangyuan Zhao